Open AccessLeveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use
Author(s) -
Rebecca N Jerome,
Meghan M. Joly,
Nan Kennedy,
Jana Shirey-Rice,
Dan M. Roden,
Gordon R. Bernard,
Kenneth J. Holroyd,
Joshua C. Denny,
Jill M. Pulley
Publication year - 2020
Publication title -
drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.377
H-Index - 124
eISSN - 1179-1942
pISSN - 0114-5916
DOI - 10.1007/s40264-020-00915-6
Subject(s) - medicine , computational biology , drug class , pharmacogenomics , drug , phenome , clinical trial , in silico , bioinformatics , drug development , gene , pharmacology , phenotype , genetics , biology
When a new drug or biologic product enters the market, its full spectrum of side effects is not yet fully understood, as use in the real world often uncovers nuances not suggested within the relatively narrow confines of preapproval preclinical and trial work.